Mumbai: Hyderabad-based

孟买：海得拉巴-based

Bharat Biotech

巴拉特生物技术公司

, which rose to global prominence during the

，这在全球范围内声名鹊起的过程中

Covid-19

新冠肺炎

pandemic with its Covaxin, is now working on a novel vaccine strategy aimed to tackle

大流行病及其Covaxin疫苗，现在正致力于开发一种新的疫苗策略以应对

antimicrobial resistance

抗菌素耐药性

(AMR), one of the most pressing public health threats globally.

(AMR)，全球最紧迫的公共卫生威胁之一。

The company is positioning itself for the next phase of growth with a strong vaccine pipeline and new bets in advanced cell and gene therapies, Raches Ella, chief development officer at Bharat Biotech, told ET in an exclusive interaction.

巴拉特生物技术公司首席开发官拉切斯·艾拉在一次独家交流中告诉《经济时报》，公司正在通过强大的疫苗管道和在先进细胞和基因治疗领域的新投资，为下一阶段的增长做好定位。

The company is in the process of developing vaccines that could be administered ahead of surgeries to prevent

公司正在开发可在手术前接种以预防的疫苗的过程中。

hospital-acquired infections

医院获得性感染

, an area where treatment options are increasingly limited due to rising drug resistance, Ella told ET.

，艾拉告诉ET，在这个治疗选择因药物抗性上升而日益受限的领域。

Also read:

另请阅读：

Zydus partners with Lupin to co-market generic semaglutide in India

Zydus与Lupin合作，在印度共同推广仿制司美鲁肽。

'Post pandemic, AMR is a big issue...we're making a conscious effort to start developing vaccines targeting these bugs,' Ella said. 'There could be a model where patients undergoing elective surgery are vaccinated in advance against specific pathogens.'

“疫情后，抗生素耐药性是一个大问题……我们正在有意识地努力开始研发针对这些病菌的疫苗，”埃拉说。“可能会有一种模式，即接受择期手术的患者提前接种针对特定病原体的疫苗。”

Live Events

现场活动

The company's focus on AMR comes amid a growing burden of

公司对AMR的关注正值负担日益加重之际

drug-resistant infections

耐药性感染

. Nearly one million deaths annually in India are linked to AMR, while globally about five million people die each year due to such infections. The scale of the threat is expected to worsen significantly. AMR could cause 10 million deaths annually by 2050 and cost the global economy up to $100 trillion in lost output if left unaddressed, according to the Review on Antimicrobial Resistance chaired by Jim O'Neill..

印度每年有近一百万例死亡与抗菌素耐药性（AMR）相关，而全球每年约有五百万人死于此类感染。这一威胁的规模预计会显著加剧。根据吉姆·奥尼尔（Jim O'Neill）主持的《抗菌素耐药性评估报告》指出，如果不采取措施，到2050年，AMR可能导致每年一千万人死亡，并使全球经济因产出损失付出高达100万亿美元的代价。

Ella pointed to the rising incidence of hospital-acquired infections as a key driver behind the company's focus. 'We think there'll be a huge demand from patients,' he said, adding that it could potentially be a part of the protocol where the vaccine can be taken a month before any surgery.

埃拉指出，医院获得性感染的发病率不断上升是公司关注的重点背后的关键驱动因素。他说：“我们认为患者的需求会很大，”他补充说，这可能会成为协议的一部分，即在任何手术前一个月接种疫苗。

Bharat Biotech also continues to double down on vaccines, its core strength. 'Vaccines are still a very exciting space to be in,' Ella said, adding that the company has four novel vaccines entering phase three efficacy trials.

巴拉特生物技术公司也继续专注于其核心优势——疫苗。艾拉表示：“疫苗领域仍然是一个非常令人兴奋的领域。”他补充说，该公司有四种新型疫苗进入三期效力试验。

These include a tuberculosis candidate, which is set to undergo one of India's largest clinical trials involving over 30,000 participants. 'The world doesn't have effective tuberculosis vaccines,' he said. The company's pipeline also includes vaccines for diarrheal pathogens Shigella and Salmonella as well as one for Chikungunya, a mosquito-borne viral disease..

这些疫苗包括一种结核病候选疫苗，该疫苗将进行印度规模最大的临床试验之一，涉及超过3万名参与者。他说：“世界上还没有有效的结核病疫苗。”该公司的研发管线中还包括针对痢疾病原体志贺氏菌和沙门氏菌的疫苗，以及一种针对蚊媒病毒性疾病基孔肯雅热的疫苗。

Weight-loss drug boom:

减肥药热潮：

Will cheaper Ozempic generics shake up India’s fitness and nutrition industry?

更便宜的Ozempic仿制药会撼动印度的健身和营养行业吗？

'We're hopeful that next year sometime, if the phase 3 readout is positive, we'll have India's first

“我们希望明年某个时候，如果第三阶段的试验结果是积极的，我们将拥有印度的第一个

Chikungunya vaccine

基孔肯雅热疫苗

,' he added.

“，”他补充道。

The company is also expanding into next generation biotherapeutics, particularly cell and

公司还正在扩展到下一代生物疗法，特别是细胞和基因治疗领域，

gene therapy

基因治疗

, with a planned investment of $75 million over the next three years.

，计划在未来三年投资7500万美元。

However, he said the segment faces significant challenges, especially around scalability and cost.

然而，他说这一领域面临重大挑战，尤其是在可扩展性和成本方面。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)